3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Respiratory Tract Diseases
1
Neoplasms
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Pemetrexed
23
Carboplatin
21
Cisplatin
20
pembrolizumab
15
Docetaxel
14
Paclitaxel
10
Gemcitabine
8
Drug Therapy
7
Bevacizumab
7
Gefitinib
5
Radiotherapy
4
Magnetic Resonance Spectroscopy
4
Erlotinib Hydrochloride
4
130-nm albumin-bound paclitaxel
4
cemiplimab
3
atezolizumab
3
anlotinib
3
Dexamethasone
3
dexamethasone acetate
2
dexamethasone 21-phosphate
2
cobimetinib
2
auricularum
2
aumolertinib
2
apatinib
2
Vemurafenib
2
Topotecan
2
Temozolomide
2
Surgical Procedures, Operative
2
Standard of Care
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
AZD3759
×
Thoracic
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled